250 related articles for article (PubMed ID: 1794035)
21. Two innovative pharmaceutical forms of leuprorelin: results from 818 patients with advanced prostate cancer.
Gravel P; Samland D; Löffler M; Maier S; Panozzo M; Muenzberg M
Adv Ther; 2013 Mar; 30(3):271-85. PubMed ID: 23460040
[TBL] [Abstract][Full Text] [Related]
22. Cost analysis of leuprorelin acetate in Japanese prostate cancer patients: comparison between 6-month and 3-month depot formulations.
Goto R; Uda A; Hiroi S; Iwasaki K; Takashima K; Oya M
J Med Econ; 2017 Nov; 20(11):1155-1162. PubMed ID: 28758810
[TBL] [Abstract][Full Text] [Related]
23. Preliminary clinical evaluation of leuprorelin acetate depot injection in France, in the management of prostatic cancer.
Navratil H
J Int Med Res; 1990; 18 Suppl 1():69-73. PubMed ID: 2108887
[TBL] [Abstract][Full Text] [Related]
24. Leuprorelin acetate granulomas: case reports and review of the literature.
Yasukawa K; Sawamura D; Sugawara H; Kato N
Br J Dermatol; 2005 May; 152(5):1045-7. PubMed ID: 15888168
[TBL] [Abstract][Full Text] [Related]
25. Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use in sex hormone-related conditions.
Chrisp P; Goa KL
Drugs; 1991 Feb; 41(2):254-88. PubMed ID: 1709853
[TBL] [Abstract][Full Text] [Related]
26. Leuprorelin acetate depot in advanced prostatic cancer: a phase II multicentre trial.
Rizzo M; Mazzei T; Mini E; Bartoletti R; Periti P
J Int Med Res; 1990; 18 Suppl 1():114-25. PubMed ID: 2108883
[TBL] [Abstract][Full Text] [Related]
27. Flutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in advanced prostatic cancer.
Brogden RN; Chrisp P
Drugs Aging; 1991 Mar; 1(2):104-15. PubMed ID: 1794008
[TBL] [Abstract][Full Text] [Related]
28. Advanced delivery of leuprorelin acetate for the treatment of prostatic cancer.
Merseburger AS; Roesch MC
Expert Rev Anticancer Ther; 2022 Jul; 22(7):703-715. PubMed ID: 35612551
[TBL] [Abstract][Full Text] [Related]
29. Six-month leuprorelin acetate depot formulations in advanced prostate cancer: a clinical evaluation.
Tunn UW; Gruca D; Bacher P
Clin Interv Aging; 2013; 8():457-64. PubMed ID: 23637525
[TBL] [Abstract][Full Text] [Related]
30. Current concepts in the treatment of genitourinary tract disorders in the older individual.
Atala A; Amin M
Drugs Aging; 1991 May; 1(3):176-93. PubMed ID: 1724398
[TBL] [Abstract][Full Text] [Related]
31. Formulation study of leuprorelin acetate to improve clinical performance.
Toguchi H
Clin Ther; 1992; 14 Suppl A():121-30. PubMed ID: 1606592
[TBL] [Abstract][Full Text] [Related]
32. Luteinizing hormone releasing hormone agonists: the US experience.
Nabors W; Crawford ED
J Int Med Res; 1990; 18 Suppl 1():31-4. PubMed ID: 2108884
[TBL] [Abstract][Full Text] [Related]
33. Randomized open labelled comparative study of the efficacy, safety and tolerability of leuprorelin acetate 1M and 3M depot in patients with advanced prostatic cancer.
Wechsel HW; Zerbib M; Pagano F; Coptcoat MJ
Eur Urol; 1996; 30 Suppl 1():7-14; discussion 19-21. PubMed ID: 8977984
[TBL] [Abstract][Full Text] [Related]
34. Treatment costs for advanced prostate cancer using luteinizing hormone-releasing hormone agonists: a solid biodegradable leuprorelin implant versus other formulations.
Merseburger AS; Björk T; Whitehouse J; Meani D
J Comp Eff Res; 2015 Sep; 4(5):447-53. PubMed ID: 25521079
[TBL] [Abstract][Full Text] [Related]
35. Combination treatment versus LHRH alone in advanced prostatic cancer.
Ferrari P; Castagnetti G; Ferrari G; Baisi B; Dotti A
Urol Int; 1996; 56 Suppl 1():13-7. PubMed ID: 8776812
[TBL] [Abstract][Full Text] [Related]
36. [Clinical phase I and phase II study on a sustained release formulation of leuprorelin acetate (TAP-144-SR), an LH-RH agonist, in patients with prostatic carcinoma. Collaborative++ Studies on Prostatic Carcinoma by the Study Group for TAP-144-SR].
Niijima T; Aso Y; Akaza H; Fujita K; Fuse H; Hosaka M; Isurugi K; Kamidono S; Katayama T; Kawabe K
Hinyokika Kiyo; 1990 Nov; 36(11):1343-60. PubMed ID: 2126912
[TBL] [Abstract][Full Text] [Related]
37. Leuprolide: a gonadotropin-releasing hormone analog for the palliative treatment of prostatic cancer.
Wojciechowski NJ; Carter CA; Skoutakis VA; Bess DT; Falbe WJ; Mickle TR
Drug Intell Clin Pharm; 1986 Oct; 20(10):746-51. PubMed ID: 2429815
[TBL] [Abstract][Full Text] [Related]
38. Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl.
Crawford ED; Moul JW; Sartor O; Shore ND
Expert Opin Drug Metab Toxicol; 2015; 11(9):1465-74. PubMed ID: 26293510
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of switching therapy of luteinizing hormone-releasing hormone analogue for advanced prostate cancer.
Shen YC; Kang CH; Chiang PH
Kaohsiung J Med Sci; 2016 Nov; 32(11):567-571. PubMed ID: 27847099
[TBL] [Abstract][Full Text] [Related]
40. Flutamide. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in advanced prostatic cancer.
Brogden RN; Clissold SP
Drugs; 1989 Aug; 38(2):185-203. PubMed ID: 2670515
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
